Britney Lizama-Manibusan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Britney Lizama-Manibusan has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- BethAnn McLaughlin
Department of Neurology, Vanderbilt University, Nashville, TN 37232, USA
4 shared publications - Amy M. Palubinsky
Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
3 shared publications - Charleen T. Chu
Department of Pathology, Division of Neuropathology, University of Pittsburgh School of Medicine, Pittsburgh, USA
2 shared publications Eunah Cho
Cognition Therapeutics, Inc., Pittsburgh, PA USA
2 shared publications- Mary E. Hamby
Cognition Therapeutics, Pittsburgh, USA
2 shared publications Valentina Di Caro
Cognition Therapeutics, Inc., Pittsburgh, PA USA
2 shared publications
Latest Publications
- Open Access
- 25 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S5) , e102120
Exploratory CSF proteomic analysis of a pre‐specified pTau217 subgroup from the SHINE clinical trial identifies biomarkers correlated with cognitive improvement in Alzheimer’s disease patients treated with zervimesine
Background: Participants with Alzheimer’s disease (AD) treated with sigma‐2 receptor (S2R) modulator zervimesine (CT1812) exhibited slowing (39% in mITT, 95% in a pre‐specified plasma‐pTau217 subgroup (below‐median at baseline)) of cognitive decline (ADAS‐Cog11) compared to placebo in the SHINE trial (NCT03507790, COG0201). Given favorable clinical outcomes in the below‐median pTau217 subgroup, correlation analysis of the CSF proteome with ADAS‐Cog11 was performed to elucidate mechanisms of zervimesine‐mediated preservation of cognition. Method: SHINE was a Phase 2 randomized, double‐blind, placebo‐controlled study. Participants (N=152) received a daily oral dose of zervimesine (100 or 300 mg) or placebo for 6‐months (end‐of‐study). The median baseline plasma‐pTau217 concentration (ALZpath, SIMOA) designated participants into subgroups below median (<1 pg/mL, N=69) or above/equal median (≥1 pg/mL, N=69). A proteomics sub‐study of 45 participants was performed (tandem‐mass tag mass spectrometry, TMT‐MS) of baseline and 6‐month CSF. CSF from treatment‐compliant participants (N=43 mITT, N=17 below‐median) were used for further analyses. Pearson correlation analysis was performed with protein change‐from‐baseline (CFB) to ADAS‐Cog11 CFB. Pathway analyses (STRING, Metacore) were performed on correlated proteins (p≤0.01). Result: The previously‐reported mITT CSF cognitive correlates were compared to those in the below‐median pTau217 subgroup that demonstrated greater cognitive benefit with zervimesine versus placebo. In this subgroup, 106 proteins correlated with ADAS‐Cog11 (p≤0.01), exhibiting enrichment in amyloid biology and immune response pathways (p≤0.05). To elucidate the biological underpinnings of robust pharmacodynamic correlates of cognitive improvement, pathway analysis was performed on 62 proteins that correlated with ADAS‐Cog11 (p≤0.01) in both mITT and below‐median pTau217 subgroup (excluding correlates (p≤0.01) in the subgroup that did not exhibit cognitive benefit with zervimesine). These 62 proteins were enriched in immune response, complement, and synapse biology pathways (FDR≤0.05). Conclusion: In a pre‐specified subgroup exhibiting 95% slowing of cognitive impairment with zervimesine, we identified protein correlates of cognition related to amyloid biology, supporting zervimesine mechanism of action. Enriching the mITT analysis with correlates from this biomarker‐defined patient population reinforced observations of immune response and synaptic pathways that correlate with cognition in both mITT and below‐median pTau217 subgroup. These biomarker findings paired with positive clinical outcomes support the further clinical development of zervimesine for AD.
- 25 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S5) , e102120
Open AccessExploratory CSF proteomic analysis of a pre‐specified pTau217 subgroup from the SHINE clinical trial identifies biomarkers correlated with cognitive improvement in Alzheimer’s disease patients treated with zervimesine
Background: Participants with Alzheimer’s disease (AD) treated with sigma‐2 receptor (S2R) modulator zervimesine (CT1812) exhibited slowing (39% in mITT, 95% in a pre‐specified plasma‐pTau217 subgroup (below‐median at baseline)) of cognitive decline (ADAS‐Cog11) compared to placebo in the SHINE trial (NCT03507790, COG0201). Given favorable clinical outcomes in the below‐median pTau217 subgroup, correlation analysis of the CSF proteome with ADAS‐Cog11 was performed to elucidate mechanisms of zervimesine‐mediated preservation of cognition. Method: SHINE was a Phase 2 randomized, double‐blind, placebo‐controlled study. Participants (N=152) received a daily oral dose of zervimesine (100 or 300 mg) or placebo for 6‐months (end‐of‐study). The median baseline plasma‐pTau217 concentration (ALZpath, SIMOA) designated participants into subgroups below median (<1 pg/mL, N=69) or above/equal median (≥1 pg/mL, N=69). A proteomics sub‐study of 45 participants was performed (tandem‐mass tag mass spectrometry, TMT‐MS) of baseline and 6‐month CSF. CSF from treatment‐compliant participants (N=43 mITT, N=17 below‐median) were used for further analyses. Pearson correlation analysis was performed with protein change‐from‐baseline (CFB) to ADAS‐Cog11 CFB. Pathway analyses (STRING, Metacore) were performed on correlated proteins (p≤0.01). Result: The previously‐reported mITT CSF cognitive correlates were compared to those in the below‐median pTau217 subgroup that demonstrated greater cognitive benefit with zervimesine versus placebo. In this subgroup, 106 proteins correlated with ADAS‐Cog11 (p≤0.01), exhibiting enrichment in amyloid biology and immune response pathways (p≤0.05). To elucidate the biological underpinnings of robust pharmacodynamic correlates of cognitive improvement, pathway analysis was performed on 62 proteins that correlated with ADAS‐Cog11 (p≤0.01) in both mITT and below‐median pTau217 subgroup (excluding correlates (p≤0.01) in the subgroup that did not exhibit cognitive benefit with zervimesine). These 62 proteins were enriched in immune response, complement, and synapse biology pathways (FDR≤0.05). Conclusion: In a pre‐specified subgroup exhibiting 95% slowing of cognitive impairment with zervimesine, we identified protein correlates of cognition related to amyloid biology, supporting zervimesine mechanism of action. Enriching the mITT analysis with correlates from this biomarker‐defined patient population reinforced observations of immune response and synaptic pathways that correlate with cognition in both mITT and below‐median pTau217 subgroup. These biomarker findings paired with positive clinical outcomes support the further clinical development of zervimesine for AD.
- Open Access
- 10 February 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-15
Sigma-2 receptor modulator CT1812 alters key pathways and rescues retinal pigment epithelium (RPE) functional deficits associated with dry age-related macular degeneration (AMD)
Trafficking defects in retinal pigmented epithelial (RPE) cells contribute to RPE atrophy, a hallmark of geographic atrophy (GA) in dry age-related macular degeneration (AMD). Dry AMD pathogenesis is multifactorial, including amyloid-β (Aβ) accumulation and oxidative stress—common features of Alzheimer’s disease (AD). The Sigma-2 receptor (S2R) regulates lipid and protein trafficking, and S2R modulators reverse trafficking deficits in neurodegeneration in vitro models. Given overlapping mechanisms contributing to AD and AMD, S2R modulator effects on RPE function were investigated. The S2R modulator CT1812 is in clinical trials for AD, dementia with Lewy bodies, and GA. Leveraging AD trials testing CT1812, unbiased analyses of patient biofluid proteomes revealed that proteins altered by CT1812 associated with GA and macular degeneration disease ontologies and overlapped with proteins altered in dry AMD. Differential expression analysis of RPE transcripts from APP-Swedish/London mutant transgenic mice, a model featuring Aβ accumulation, revealed reversal of autophagy/trafficking transcripts in S2R modulator-treated animals versus vehicle toward healthy control levels. Photoreceptor outer segment (POS) trafficking in human RPE cells showed deficits in response to Aβ1−42 or hydrogen peroxide compared to vehicle. S2R modulators normalized stressor-induced POS trafficking deficits, resembling healthy control. Taken together, S2R modulation may provide a novel therapeutic strategy for dry AMD.
- 10 February 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-15
Open AccessSigma-2 receptor modulator CT1812 alters key pathways and rescues retinal pigment epithelium (RPE) functional deficits associated with dry age-related macular degeneration (AMD)
Trafficking defects in retinal pigmented epithelial (RPE) cells contribute to RPE atrophy, a hallmark of geographic atrophy (GA) in dry age-related macular degeneration (AMD). Dry AMD pathogenesis is multifactorial, including amyloid-β (Aβ) accumulation and oxidative stress—common features of Alzheimer’s disease (AD). The Sigma-2 receptor (S2R) regulates lipid and protein trafficking, and S2R modulators reverse trafficking deficits in neurodegeneration in vitro models. Given overlapping mechanisms contributing to AD and AMD, S2R modulator effects on RPE function were investigated. The S2R modulator CT1812 is in clinical trials for AD, dementia with Lewy bodies, and GA. Leveraging AD trials testing CT1812, unbiased analyses of patient biofluid proteomes revealed that proteins altered by CT1812 associated with GA and macular degeneration disease ontologies and overlapped with proteins altered in dry AMD. Differential expression analysis of RPE transcripts from APP-Swedish/London mutant transgenic mice, a model featuring Aβ accumulation, revealed reversal of autophagy/trafficking transcripts in S2R modulator-treated animals versus vehicle toward healthy control levels. Photoreceptor outer segment (POS) trafficking in human RPE cells showed deficits in response to Aβ1−42 or hydrogen peroxide compared to vehicle. S2R modulators normalized stressor-induced POS trafficking deficits, resembling healthy control. Taken together, S2R modulation may provide a novel therapeutic strategy for dry AMD.
- Open Access
- 26 March 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (7) , 6251
Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases
There is a large unmet medical need to develop disease-modifying treatment options for individuals with age-related degenerative diseases of the central nervous system. The sigma-2 receptor (S2R), encoded by TMEM97, is expressed in brain and retinal cells, and regulates cell functions via its co-receptor progesterone receptor membrane component 1 (PGRMC1), and through other protein–protein interactions. Studies describing functions of S2R involve the manipulation of expression or pharmacological modulation using exogenous small-molecule ligands. These studies demonstrate that S2R modulates key pathways involved in age-related diseases including autophagy, trafficking, oxidative stress, and amyloid-β and α-synuclein toxicity. Furthermore, S2R modulation can ameliorate functional deficits in cell-based and animal models of disease. This review summarizes the current evidence-based understanding of S2R biology and function, and its potential as a therapeutic target for age-related degenerative diseases of the central nervous system, including Alzheimer’s disease, α-synucleinopathies, and dry age-related macular degeneration.
- 26 March 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (7) , 6251
Open AccessSigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases
There is a large unmet medical need to develop disease-modifying treatment options for individuals with age-related degenerative diseases of the central nervous system. The sigma-2 receptor (S2R), encoded by TMEM97, is expressed in brain and retinal cells, and regulates cell functions via its co-receptor progesterone receptor membrane component 1 (PGRMC1), and through other protein–protein interactions. Studies describing functions of S2R involve the manipulation of expression or pharmacological modulation using exogenous small-molecule ligands. These studies demonstrate that S2R modulates key pathways involved in age-related diseases including autophagy, trafficking, oxidative stress, and amyloid-β and α-synuclein toxicity. Furthermore, S2R modulation can ameliorate functional deficits in cell-based and animal models of disease. This review summarizes the current evidence-based understanding of S2R biology and function, and its potential as a therapeutic target for age-related degenerative diseases of the central nervous system, including Alzheimer’s disease, α-synucleinopathies, and dry age-related macular degeneration.
- 7 September 2022
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 42 (41) , 7848-7860
Endogenous PTEN-induced kinase 1 regulates dendritic architecture and spinogenesis
Mutations in PTEN-induced kinase 1 (PINK1) contribute to autosomal recessive Parkinson9s disease with cognitive and neuropsychiatric comorbidities. Disturbances in dendritic and spine architecture are hallmarks of neurodegenerative and neuropsychiatric conditions, but little is known of the impact of PINK1 on these structures. We used Pink1−/− mice to study the role of endogenous PINK1 in regulating dendritic architecture, spine density, and spine maturation. Pink1−/− cortical neurons of unknown sex showed decreased dendritic arborization, affecting both apical and basal arbors. Dendritic simplification in Pink1−/− neurons was primarily driven by diminished branching with smaller effects on branch lengths. Pink1−/− neurons showed reduced spine density with a shift in morphology to favor filopodia at the expense of mushroom spines. Electrophysiology revealed significant reductions in miniature EPSC (mEPSC) frequency in Pink1−/− neurons, consistent with the observation of decreased spine numbers. Transfecting with human PINK1 rescued changes in dendritic architecture, in thin, stubby, and mushroom spine densities, and in mEPSC frequency. Diminished spine density was also observed in Golgi–Cox stained adult male Pink1−/− brains. Western blot study of Pink1−/− brains of either sex revealed reduced phosphorylation of NSFL1 cofactor p47, an indirect target of PINK1. Transfection of Pink1−/− neurons with a phosphomimetic p47 plasmid rescued dendritic branching and thin/stubby spine density with a partial rescue of mushroom spines, implicating a role for PINK1-regulated p47 phosphorylation in dendrite and spine development. These findings suggest that PINK1-dependent synaptodendritic alterations may contribute to the risk of cognitive and/or neuropsychiatric pathologies observed in PINK1-mutated families. SIGNIFICANCE STATEMENT Loss of PINK1 function has been implicated in both familial and sporadic neurodegenerative diseases. Yet surprisingly little is known of the impact of PINK1 loss on the fine structure of neurons. Neurons receive excitatory synaptic signals along a complex network of projections that form the dendritic tree, largely at tiny protrusions called dendritic spines. We studied cortical neurons and brain tissues from mice lacking PINK1. We discovered that PINK1 deficiency causes striking simplification of dendritic architecture associated with reduced synaptic input and decreased spine density and maturation. These changes are reversed by reintroducing human PINK1 or one of its downstream mediators into PINK1-deficient mouse neurons, indicating a conserved function, whose loss may contribute to neurodegenerative processes.
- 7 September 2022
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 42 (41) , 7848-7860
Endogenous PTEN-induced kinase 1 regulates dendritic architecture and spinogenesis
Mutations in PTEN-induced kinase 1 (PINK1) contribute to autosomal recessive Parkinson9s disease with cognitive and neuropsychiatric comorbidities. Disturbances in dendritic and spine architecture are hallmarks of neurodegenerative and neuropsychiatric conditions, but little is known of the impact of PINK1 on these structures. We used Pink1−/− mice to study the role of endogenous PINK1 in regulating dendritic architecture, spine density, and spine maturation. Pink1−/− cortical neurons of unknown sex showed decreased dendritic arborization, affecting both apical and basal arbors. Dendritic simplification in Pink1−/− neurons was primarily driven by diminished branching with smaller effects on branch lengths. Pink1−/− neurons showed reduced spine density with a shift in morphology to favor filopodia at the expense of mushroom spines. Electrophysiology revealed significant reductions in miniature EPSC (mEPSC) frequency in Pink1−/− neurons, consistent with the observation of decreased spine numbers. Transfecting with human PINK1 rescued changes in dendritic architecture, in thin, stubby, and mushroom spine densities, and in mEPSC frequency. Diminished spine density was also observed in Golgi–Cox stained adult male Pink1−/− brains. Western blot study of Pink1−/− brains of either sex revealed reduced phosphorylation of NSFL1 cofactor p47, an indirect target of PINK1. Transfection of Pink1−/− neurons with a phosphomimetic p47 plasmid rescued dendritic branching and thin/stubby spine density with a partial rescue of mushroom spines, implicating a role for PINK1-regulated p47 phosphorylation in dendrite and spine development. These findings suggest that PINK1-dependent synaptodendritic alterations may contribute to the risk of cognitive and/or neuropsychiatric pathologies observed in PINK1-mutated families. SIGNIFICANCE STATEMENT Loss of PINK1 function has been implicated in both familial and sporadic neurodegenerative diseases. Yet surprisingly little is known of the impact of PINK1 loss on the fine structure of neurons. Neurons receive excitatory synaptic signals along a complex network of projections that form the dendritic tree, largely at tiny protrusions called dendritic spines. We studied cortical neurons and brain tissues from mice lacking PINK1. We discovered that PINK1 deficiency causes striking simplification of dendritic architecture associated with reduced synaptic input and decreased spine density and maturation. These changes are reversed by reintroducing human PINK1 or one of its downstream mediators into PINK1-deficient mouse neurons, indicating a conserved function, whose loss may contribute to neurodegenerative processes.
- 12 June 2021
- Published by Elsevier in Molecular Aspects of Medicine
- Vol. 82, 100972
Neuronal autophagy and mitophagy in Parkinson's disease
- 12 June 2021
- Published by Elsevier in Molecular Aspects of Medicine
- Vol. 82, 100972
Neuronal autophagy and mitophagy in Parkinson's disease
- Open Access
- 22 June 2018
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 38 (31) , 6825-6840
Neuronal Preconditioning Requires the Mitophagic Activity of C-terminus of HSC70-Interacting Protein
The C terminus of HSC70-interacting protein (CHIP, STUB1) is a ubiquitously expressed cytosolic E3-ubiquitin ligase. CHIP-deficient mice exhibit cardiovascular stress and motor dysfunction before premature death. This phenotype is more consistent with animal models in which master regulators of autophagy are affected rather than with the mild phenotype of classic E3-ubiquitin ligase mutants. The cellular and biochemical events that contribute to neurodegeneration and premature aging in CHIP KO models remain poorly understood. Electron and fluorescent microscopy demonstrates that CHIP deficiency is associated with greater numbers of mitochondria, but these organelles are swollen and misshapen. Acute bioenergetic stress triggers CHIP induction and relocalization to mitochondria, where it plays a role in the removal of damaged organelles. This mitochondrial clearance is required for protection following low-level bioenergetic stress in neurons. CHIP expression overlaps with stabilization of the redox stress sensor PTEN-inducible kinase 1 (PINK1) and is associated with increased LC3-mediated mitophagy. Introducing human promoter-driven vectors with mutations in either the E3 ligase or tetracopeptide repeat domains of CHIP in primary neurons derived from CHIP-null animals enhances CHIP accumulation at mitochondria. Exposure to autophagy inhibitors suggests that the increase in mitochondrial CHIP is likely due to diminished clearance of these CHIP-tagged organelles. Proteomic analysis of WT and CHIP KO mouse brains (four male, four female per genotype) reveals proteins essential for maintaining energetic, redox, and mitochondrial homeostasis undergo significant genotype-dependent expression changes. Together, these data support the use of CHIP-deficient animals as a predictive model of age-related degeneration with selective neuronal proteotoxicity and mitochondrial failure. SIGNIFICANCE STATEMENT Mitochondria are recognized as central determinants of neuronal function and survival. We demonstrate that C terminus of HSC70-Interacting Protein (CHIP) is critical for neuronal responses to stress. CHIP upregulation and localization to mitochondria is required for mitochondrial autophagy (mitophagy). Unlike other disease-associated E3 ligases such as Parkin and Mahogunin, CHIP controls homeostatic and stress-induced removal of mitochondria. Although CHIP deletion results in greater numbers of mitochondria, these organelles have distorted inner membranes without clear cristae. Neuronal cultures derived from animals lacking CHIP are more vulnerable to acute injuries and transient loss of CHIP renders neurons incapable of mounting a protective response after low-level stress. Together, these data suggest that CHIP is an essential regulator of mitochondrial number, cell signaling, and survival.
- 22 June 2018
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 38 (31) , 6825-6840
Open AccessNeuronal Preconditioning Requires the Mitophagic Activity of C-terminus of HSC70-Interacting Protein
The C terminus of HSC70-interacting protein (CHIP, STUB1) is a ubiquitously expressed cytosolic E3-ubiquitin ligase. CHIP-deficient mice exhibit cardiovascular stress and motor dysfunction before premature death. This phenotype is more consistent with animal models in which master regulators of autophagy are affected rather than with the mild phenotype of classic E3-ubiquitin ligase mutants. The cellular and biochemical events that contribute to neurodegeneration and premature aging in CHIP KO models remain poorly understood. Electron and fluorescent microscopy demonstrates that CHIP deficiency is associated with greater numbers of mitochondria, but these organelles are swollen and misshapen. Acute bioenergetic stress triggers CHIP induction and relocalization to mitochondria, where it plays a role in the removal of damaged organelles. This mitochondrial clearance is required for protection following low-level bioenergetic stress in neurons. CHIP expression overlaps with stabilization of the redox stress sensor PTEN-inducible kinase 1 (PINK1) and is associated with increased LC3-mediated mitophagy. Introducing human promoter-driven vectors with mutations in either the E3 ligase or tetracopeptide repeat domains of CHIP in primary neurons derived from CHIP-null animals enhances CHIP accumulation at mitochondria. Exposure to autophagy inhibitors suggests that the increase in mitochondrial CHIP is likely due to diminished clearance of these CHIP-tagged organelles. Proteomic analysis of WT and CHIP KO mouse brains (four male, four female per genotype) reveals proteins essential for maintaining energetic, redox, and mitochondrial homeostasis undergo significant genotype-dependent expression changes. Together, these data support the use of CHIP-deficient animals as a predictive model of age-related degeneration with selective neuronal proteotoxicity and mitochondrial failure. SIGNIFICANCE STATEMENT Mitochondria are recognized as central determinants of neuronal function and survival. We demonstrate that C terminus of HSC70-Interacting Protein (CHIP) is critical for neuronal responses to stress. CHIP upregulation and localization to mitochondria is required for mitochondrial autophagy (mitophagy). Unlike other disease-associated E3 ligases such as Parkin and Mahogunin, CHIP controls homeostatic and stress-induced removal of mitochondria. Although CHIP deletion results in greater numbers of mitochondria, these organelles have distorted inner membranes without clear cristae. Neuronal cultures derived from animals lacking CHIP are more vulnerable to acute injuries and transient loss of CHIP renders neurons incapable of mounting a protective response after low-level stress. Together, these data suggest that CHIP is an essential regulator of mitochondrial number, cell signaling, and survival.
- 24 August 2016
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 7 (9) , 1188-1191
Analysis of a Nitroreductase-Based Hypoxia Sensor in Primary Neuronal Cultures
The ability to assess oxygenation within living cells is much sought after to more deeply understand normal and pathological cell biology. Hypoxia Red manufactured by Enzo Life Sciences is advertised as a novel hypoxia detector dependent on nitroreducatase activity. We sought to use Hypoxia Red in primary neuronal cultures to test cell-to-cell metabolic variability in response to hypoxic stress. Neurons treated with 90 min of hypoxia were labeled with Hypoxia Red. We observed that, even under normoxic conditions neurons expressed fluorescence robustly. Analysis of the chemical reactions and biological underpinnings of this method revealed that the high uptake and reduction of the dye is due to active nitroreductases in normoxic cells that are independent of oxygen availability.
- 24 August 2016
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 7 (9) , 1188-1191
Analysis of a Nitroreductase-Based Hypoxia Sensor in Primary Neuronal Cultures
The ability to assess oxygenation within living cells is much sought after to more deeply understand normal and pathological cell biology. Hypoxia Red manufactured by Enzo Life Sciences is advertised as a novel hypoxia detector dependent on nitroreducatase activity. We sought to use Hypoxia Red in primary neuronal cultures to test cell-to-cell metabolic variability in response to hypoxic stress. Neurons treated with 90 min of hypoxia were labeled with Hypoxia Red. We observed that, even under normoxic conditions neurons expressed fluorescence robustly. Analysis of the chemical reactions and biological underpinnings of this method revealed that the high uptake and reduction of the dye is due to active nitroreductases in normoxic cells that are independent of oxygen availability.
- 1 January 2015
- Published by Elsevier
- p. 289-314
Genetic Models of Parkinson’s Disease
- 1 January 2015
- Published by Elsevier
Contributors
- 14 June 2013
- Published by Wiley in FEBS Letters
- Vol. 587 (15) , 2291-2298
Redox modification of proteins as essential mediators of CNS autophagy and mitophagy
Production of cellular reactive oxygen species (ROS) is typically associated with protein and DNA damage, toxicity, and death. However, ROS are also essential regulators of signaling and work in concert with redox‐sensitive proteins to regulate cell homeostasis during stress. In this review, we focus on the redox regulation of mitophagy, a process that contributes to energetic tone as well as mitochondrial form and function. Mitophagy has been increasingly implicated in diseases including Parkinson's, Amyotrophic Lateral Sclerosis, and cancer. Although these disease states employ different genetic mutations, they share the common factors of redox dysregulation and autophagic signaling. This review highlights key redox sensitive signaling molecules which can enhance neuronal survival by promoting temporally and spatially controlled autophagic signaling and mitophagy.
- 14 June 2013
- Published by Wiley in FEBS Letters
- Vol. 587 (15) , 2291-2298
Redox modification of proteins as essential mediators of CNS autophagy and mitophagy
Production of cellular reactive oxygen species (ROS) is typically associated with protein and DNA damage, toxicity, and death. However, ROS are also essential regulators of signaling and work in concert with redox‐sensitive proteins to regulate cell homeostasis during stress. In this review, we focus on the redox regulation of mitophagy, a process that contributes to energetic tone as well as mitochondrial form and function. Mitophagy has been increasingly implicated in diseases including Parkinson's, Amyotrophic Lateral Sclerosis, and cancer. Although these disease states employ different genetic mutations, they share the common factors of redox dysregulation and autophagic signaling. This review highlights key redox sensitive signaling molecules which can enhance neuronal survival by promoting temporally and spatially controlled autophagic signaling and mitophagy.